- Symbiotec Pharmalab's IPO opens with a valuation of ₹1,757 crore, primarily as an offer for sale, including only ₹150 crore as a fresh issue.
- Symbiotec leads the global corticosteroid market with a 38.2% volume share and the steroidal hormone market with a 23.8% volume share.
- Revenue growth for the company has been 10% annually over the past two years, while profit growth has stagnated at 5%, leading to a decline in return on equity from 14% to 11.2%.
- New injectables and fermentation plants were commissioned in March 2026, but they are still running pilot batches and awaiting necessary approvals.
- The first two injectable products are expected to launch in FY27 and could command a premium of 20-50% over conventional vials.
- Symbiotec's revenue mix is heavily reliant on ingredient sales, which accounted for 96% of total revenue in FY26.
- Exports have increased to 67% of revenue, up from 55% the previous year, driven by significant growth in the American market.
- Symbiotec's new injectable business generated ₹33 crore in FY26, a significant increase from zero the previous year.
- Symbiotec has invested ₹970 crore in its new injectables and fermentation plants, which are currently a drag on earnings.
- Loss-making subsidiaries have contributed to stagnating profits, with these new ventures losing ₹28.5 crore in FY26.
Symbiotec Pharmalab's IPO opens with a valuation of ₹1,757 crore, primarily as an offer for sale, with only ₹150 crore from a fresh issue. The company is a leader in the fermentation APIs and complex injectables market, boasting a significant global presence.1
In the corticosteroid sector, Symbiotec holds 38.2 per cent of the global market share, while its steroidal hormone volume accounts for 23.8 per cent. The company sells over 60 ingredients to more than 200 customers, with a revenue mix heavily skewed towards ingredient sales, which contributed 96 per cent of total revenue in FY26.
Exports have surged, now making up 67 per cent of revenue, a rise from 55 per cent the previous year, driven by a significant increase in sales to the U.S., which jumped from ₹30 crore to ₹114 crore. However, domestic sales have declined from ₹337 crore to ₹287 crore.89
The company’s customer retention is notable, with top clients maintaining relationships for over 10 years on average, contributing 69.5 per cent of FY26 revenue. Its new injectable business, which generated ₹33 crore in FY26, is expected to launch two products in FY27, potentially commanding a 20 to 50 per cent premium over traditional vials.
Despite these strengths, the IPO is priced at 58 times earnings, a high valuation for a business with 10 per cent annual revenue growth and 5 per cent profit growth over the past two years. Return on equity has also declined to 11.2 per cent in FY26 from 14 per cent two years prior.34
“The company leads global corticosteroid and steroidal hormone markets with 38.2% and 23.8% volume shares, but its new plants are yet to produce commercially and subsidiaries lost ₹28.5 crore in FY26. Exports rose to 67% of revenue, driven by American sales jumping from ₹30 crore to ₹114 crore.”
Value Research
/entrackr/media/media_files/2026/08/24/asaya-2026-08-24-10-31-37.png)
